Back to results
US 12,605,457 B2Granted
Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof
AssigneeBliss Biopharmaceutical (Hangzhou) Co., Ltd.
InventorsBing Xia, Yuhong Zhou, Ziping Wei, Lixia Cao, Fangdun Jiang
Life of this patent
Estimating the term…
Abstract
The present invention provides isolated antibodies that bind to the human EGFR protein, and ADCs of the antibodies. Pharmaceutical compositions including the antibodies and ADCs, and methods of treating cancer are also provided.
Claims19
An isolated antibody comprising:
- (a1) a heavy chain variable domain comprising a CDR1 region, a CDR2 region, and a CDR3 region comprising the amino acid sequences of SEQ ID NO:
- 14, SEQ ID NO:
- 15, and SEQ ID NO:
- 18, respectively, and (b1) a light chain variable domain comprising a CDR1 region, a CDR2 region, and a CDR3 region comprising the amino acid sequences of SEQ ID NO:
- 20, SEQ ID NO:
- 21, and SEQ ID NO:
- 23, respectively;
- or
- (a2) a heavy chain variable domain comprising a CDR1 region, a CDR2 region, and a CDR3 region comprising the amino acid sequences of SEQ ID NO:
- 14, SEQ ID NO:
- 16, and SEQ ID NO:
- 17, respectively, and (b2) a light chain variable domain comprising a CDR1 region, a CDR2 region, and a CDR3 region comprising the amino acid sequences of SEQ ID NO:
- 19, SEQ ID NO:
- 22, and SEQ ID NO:
- 23, respectively;
- or
- (a3) a heavy chain variable domain comprising a CDR1 region, a CDR2 region, and a CDR3 region comprising the amino acid sequences of SEQ ID NO:
- 14, SEQ ID NO:
- 15, and SEQ ID NO:
- 18, respectively, and (b3) a light chain variable domain comprising a CDR1 region, a CDR2 region, and a CDR3 region comprising the amino acid sequences of SEQ ID NO:
- 20, SEQ ID NO:
- 22, and SEQ ID NO:
- 23, respectively;
- (a4) a heavy chain variable domain comprising a CDR1 region, a CDR2 region, and a CDR3 region comprising the amino acid sequences of SEQ ID NO:
- 14, SEQ ID NO:
- 16, and SEQ ID NO:
- 18, respectively, and (b4) a light chain variable domain comprising a CDR1 region, a CDR2 region, and a CDR3 region comprising the amino acid sequences of SEQ ID NO:
- 20, SEQ ID NO:
- 21, and SEQ ID NO:
- 23, respectively;
- wherein the isolated antibody specifically binds with human EGFR protein.
28 more elements
An isolated antibody comprising:
- (a) a heavy chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 1, and a light chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 4;
- or
- (b) a heavy chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 5, and a light chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 6;
- or
- (c) a heavy chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 1, and a light chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 2;
- or
- (d) a heavy chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 3, and a light chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 4.
12 more elements
An isolated antibody comprising:
- (a) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 7, and a light chain comprising the amino acid sequence of SEQ ID NO:
- 10;
- or
- (b) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 13, and a light chain comprising the amino acid sequence of SEQ ID NO:
- 10;
- or
- (c) a heavy chain comprising the amino acid sequence of SEQ TD NO:
- 11, and a light chain comprising the amino acid sequence of SEQ ID NO:
- 12;
- or
- (d) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 7, and a light chain comprising the amino acid sequence of SEQ ID NO:
- 8;
- or
- (e) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 9, and a light chain comprising the amino acid sequence of SEQ ID NO:
- 10.
16 more elements
Dependencies are inferred from the claim text.